Valuation Metrics: A Closer Look
As of 12 Feb 2026, Laurus Labs trades at ₹1,012.45, up 4.85% from the previous close of ₹965.65. The stock’s 52-week range spans from ₹512.05 to ₹1,140.90, reflecting significant volatility and a strong upward trend over the past year. However, the recent upgrade in valuation grade from "expensive" to "very expensive" warrants a detailed examination of the underlying financial ratios driving this change.
The company’s current P/E ratio stands at 64.81, a substantial premium compared to many of its pharmaceutical peers. For context, Lupin and Zydus Lifesciences trade at P/E ratios of 23.38 and 17.42 respectively, while Mankind Pharma and Alkem Laboratories are at 46.04 and 29.93. Even Abbott India, classified as very expensive, has a P/E of 37.98, significantly lower than Laurus Labs.
Similarly, Laurus Labs’ price-to-book value ratio is 11.37, indicating investors are paying over eleven times the company’s net asset value. This is markedly higher than the sector average and peers such as Aurobindo Pharma (P/BV not specified but valuation attractive) and Glenmark Pharma, which are considered more reasonably priced.
Comparative Enterprise Value Multiples
Enterprise value (EV) multiples further illustrate Laurus Labs’ premium valuation. The EV to EBIT ratio is 46.65, and EV to EBITDA is 33.69, both considerably elevated relative to peers. For example, Lupin’s EV to EBITDA is 14.98, and Zydus Lifesciences stands at 11.55. These multiples suggest that the market is pricing in robust future earnings growth and operational efficiency, but also imply limited margin for error if growth expectations are not met.
The EV to capital employed ratio of 8.17 and EV to sales of 8.45 reinforce the narrative of a richly valued stock. Investors appear confident in Laurus Labs’ ability to generate returns on capital, supported by its latest return on capital employed (ROCE) of 14.92% and return on equity (ROE) of 14.23%. These figures are respectable within the sector, indicating efficient utilisation of capital and shareholder funds.
PEG Ratio and Dividend Yield Insights
The company’s PEG ratio is 0.20, which is notably low and suggests that despite the high P/E, the stock’s price growth relative to earnings growth is attractive. This low PEG ratio may justify the premium valuation to some extent, signalling that earnings growth is expected to accelerate significantly. However, investors should remain cautious as such low PEG ratios can sometimes reflect overly optimistic growth assumptions.
Dividend yield remains modest at 0.16%, indicating that Laurus Labs prioritises reinvestment and growth over shareholder payouts. This is typical for companies in high-growth phases within the pharmaceutical sector.
Stock Performance Versus Sensex
Examining stock returns relative to the benchmark Sensex provides additional context. Over the past year, Laurus Labs has delivered a stellar 65.81% return compared to Sensex’s 10.41%, underscoring strong investor confidence and operational performance. Over three and five years, the stock has outperformed the Sensex by wide margins, with returns of 197.56% and 175.61% respectively, versus 38.81% and 63.46% for the index.
Shorter-term returns are mixed, with a 1-month decline of 6.45% contrasting with a 1-week gain of 3.24%. Year-to-date, the stock is down 8.64%, slightly underperforming the Sensex’s -1.16%. These fluctuations highlight the stock’s sensitivity to market sentiment and sector-specific developments.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Peer Comparison and Sector Context
Within the Pharmaceuticals & Biotechnology sector, Laurus Labs’ valuation stands out as one of the highest. While companies like Lupin, Zydus Lifesciences, and Aurobindo Pharma are rated as attractive or very attractive based on their valuation metrics, Laurus Labs has shifted into the very expensive category. This shift reflects both the company’s strong growth prospects and the premium investors are willing to pay for its perceived quality and future earnings potential.
Notably, Biocon, despite a very high P/E of 130.7, is still considered attractive, likely due to its unique market position and growth drivers. Abbott India and GlaxoSmithKline Pharmaceuticals also fall into the very expensive category but maintain lower P/E ratios than Laurus Labs, reinforcing the latter’s premium status.
Quality Grades and Market Sentiment
MarketsMOJO assigns Laurus Labs a Mojo Score of 75.0 and a current Mojo Grade of Buy, downgraded from Strong Buy on 09 Jun 2025. The market capitalisation grade remains low at 2, reflecting mid-cap status. The downgrade in grade aligns with the valuation shift, signalling a more cautious stance despite the company’s solid fundamentals and growth trajectory.
Investors should weigh the company’s strong operational metrics, including ROCE and ROE above 14%, against the stretched valuation multiples. The low dividend yield and PEG ratio suggest a growth-oriented strategy, but the very expensive rating indicates limited margin for valuation expansion.
Investment Implications
For investors, the key question is whether Laurus Labs’ premium valuation is justified by its growth prospects and financial health. The company’s robust returns over multiple time horizons and superior operational efficiency support a positive outlook. However, the elevated P/E and P/BV ratios imply that the stock is priced for perfection, and any earnings disappointment or sector headwinds could trigger sharp corrections.
Comparing Laurus Labs to its peers reveals that while it commands a premium, alternatives with attractive valuations and solid fundamentals exist within the sector. This may prompt investors to consider a more diversified approach or wait for valuation moderation before committing fresh capital.
Thinking about Laurus Labs Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Conclusion: Valuation Premium Reflects Growth but Warrants Caution
Laurus Labs Ltd’s transition to a very expensive valuation grade underscores the market’s confidence in its growth story but also highlights the risks associated with stretched multiples. The company’s strong financial metrics, including a ROCE of 14.92% and ROE of 14.23%, support its premium rating, yet the P/E ratio of 64.81 and P/BV of 11.37 are significantly above sector averages.
Investors should carefully monitor earnings delivery and sector dynamics, as the current valuation leaves limited room for disappointment. While the stock has outperformed the Sensex substantially over the medium to long term, recent short-term volatility and a downgrade in Mojo Grade from Strong Buy to Buy suggest a more measured approach may be prudent.
Ultimately, Laurus Labs remains a compelling growth stock within Pharmaceuticals & Biotechnology, but its price attractiveness has diminished relative to peers and historical levels. A balanced portfolio strategy incorporating valuation discipline will be key to navigating this evolving investment landscape.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
